Abstract
Biochemical abnormalities associated with the development of multiple myeloma have been difficult to define especially in terms of demonstrating an in vivo effect of suspected lesions. Herein, we have identified such a defect associated with lack of expression of PTEN, a cellular phosphatase involved in the regulation of phosphatidylinositol phosphates (PIP's). In myeloma cells, PIP's are required for phosphorylation of Akt, a key event leading to inhibition of apoptosis. Loss of PTEN results in a failure to de-phosphorylate PIP's and a corresponding increase in Akt phosphorylation. OPM-2 cells lacking PTEN expression have the highest level of Akt phosphorylation of eight lines examined. Loss of PTEN was found to be associated with a 630 bp deletion corresponding to amino acids 56–267. Ectopic expression of wild type PTEN in OPM-2 cells inhibited Akt phosphorylation which was correlated with an increase in apoptosis. The in vivo relevance of loss of PTEN expression was demonstrated by injecting control and wild type PTEN transfected OPM-2 cells into SCID mice. Tumors arose at an incidence of 100% in controls, but only 50% (and of smaller size and longer latency) in low PTEN expressing clones. Importantly, clones expressing high levels of PTEN failed to produce tumors even at five times the latency period of controls. These results demonstrate that PTEN deletion/mutation is responsible for in vivo growth of this tumor and suggests that PTEN regulation may play an important role in tumor development in a subset of multiple myeloma patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anderson KC, Hamblin TJ and Traynor A. . 1999 Semin. Hematol. 36: 3–8.
Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL and Kuehl WM. . 1996 Proc. Natl. Acad. Sci. USA 93: 13931–13936.
Boni R, Vortmeyer AO, Burg G, Hofbauer G and Zhuang Z. . 1998 Melanoma Res. 8: 300–302.
Cantley LC and Neel BG. . 1999 Proc. Natl. Acad. Sci. USA 96: 4240–4245.
Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK and Steck PA. . 1999 Cancer Res. 59: 2551–2556.
Di Cristofano A, Pesce B, Cordon-Cardo C and Pandolfi PP. . 1998 Nat. Genet. 19: 348–355.
Freund GG, Kulas DT, Way BA and Mooney RA. . 1994 Cancer Res. 54: 3179–3185.
Gabrea A, Bergsagel PL, Chesi M, Shou Y and Kuehl WM. . 1999 Mol. Cell 3: 119–123.
Ge N-L and Rudikoff S. . 2000 Blood in press.
Georgii-Hemming P, Wiklund HJ, Ljunggren O and Nilsson K. . 1996 Blood 88: 2250–2258.
Ghosh AK, Grigorieva I, Steele R, Hoover RG and Ray RB. . 1999 Gene 235: 85–91.
Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G and Stokoe D. . 1998 Curr. Biol. 8: 1195–1198.
Jelinek DF, Witzig TE and Arendt BK. . 1997 J. Immunol. 159: 487–496.
Klein B and Bataille R. . 1992 Hematol. Oncol. Clin. North Am. 6: 273–284.
Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J and Bataille R. . 1990 Eur. Cytokine Netw. 1: 193–201.
Kyle RA. . 1992 Hematol. Oncol. Clin. North Am. 6: 347–358.
Ladanyi M, Wang S, Niesvizky R, Feiner H and Michaeli J. . 1992 Am. J. Pathol. 141: 949–953.
Li DM and Sun H. . 1997 Cancer Res. 57: 2124–2129.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R. . 1997 Science 275: 1943–1947.
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C and Parsons R. . 1997 Nat. Genet. 16: 64–67.
Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ and Eng C. . 1997 Nat. Genet. 16: 333–334.
Munshi NC, Barlogie B, Desikan KR and Wilson C. . 1999 Semin. Oncol. 26: 28–34.
Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B and Baserga R. . 1999 Mol. Cell. Biol. 19: 7203–7215.
Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B and Theillet C. . 1992 Oncogene 7: 2539–2543.
Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT and Neri A. . 1997 Blood 90: 4062–4070.
Risinger JI, Hayes AK, Berchuck A and Barrett JC. . 1997 Cancer Res. 57: 4736–4738.
Seiden MV and Anderson KC. . 1994 Curr. Opin. Oncol. 6: 41–49.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV. . 1997 Nat. Genet. 15: 356–362.
Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M and Mak TW. . 1998 Curr. Biol. 8: 1169–1178.
Uddin S, Yetter A, Katzav S, Hofmann C, White MF and Platanias LC. . 1996 Exp. Hematol. 24: 622–627.
Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ. . 1995 Cell 80: 285–291.
Yasuga Y, Hirosawa S, Yamamoto K, Tomiyama J, Nagata K and Aokia N. . 1995 Int. J. Hematol. 62: 91–97.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ge, NL., Rudikoff, S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene 19, 4091–4095 (2000). https://doi.org/10.1038/sj.onc.1203801
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203801
Keywords
This article is cited by
-
PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells
Clinical & Experimental Metastasis (2020)
-
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
BMC Cancer (2018)
-
Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma
Clinical Epigenetics (2014)
-
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo
Cancer Chemotherapy and Pharmacology (2013)
-
Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype
Leukemia (2012)